戻る
Arcus Biosciences Inc (RCUS)価格
RCUS 株価推移チャート
RCUS 収入
Arcus Biosciences Inc
$21.8
0.04%
$0.01
終値： Jan 16, 16:00:00 GMT-5
$21.8
0%
$0
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$21.79
始値
$22.11
当日レンジ
$21.56 - $22.45
52週レンジ
$6.5 - $26.4
取引高
975.9K
平均取引高
1.9M
1株当たり利益(TTM)
-3.43
配当利回り
--
時価総額
$2.9B
RCUSとは何ですか？
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 627 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.